![[ICO]](/icons/blank.gif) | Name | Last modified | Size | Description |
|---|
|
|---|
![[PARENTDIR]](/icons/back.gif) | Parent Directory | | - | |
![[ ]](/icons/layout.gif) | MCA_3.2_1_1_03.Parexel_ CTA.pdf | 2024-09-18 08:05 | 4.0M | |
| MCA_3.2_1_2_04.CTA_Glenmark_Asthma.pdf | 2024-09-18 08:06 | 2.0M | |
| MCA_3.2_1_3_05.Signed CTA_Amphotericin B_Dr Nikalje_MGM_Syngene (1).pdf | 2024-09-18 08:06 | 18M | |
| MCA_3.2_1_4_06.CTA _HETERO_ Dr. Lakshmi.pdf | 2024-09-18 08:06 | 2.5M | |
| MCA_3.2_1_5_07.C2A00975_ CTA Amendment_Dr. Ashish Deshmukh (1).pdf | 2024-09-18 08:06 | 1.4M | |
| MCA_3.2_1_6_08.Bevacizumab CTA.pdf | 2024-09-18 08:06 | 9.3M | |
| MCA_3.2_1_7_09.Oxygen SMO CTA (2).pdf | 2024-09-18 08:06 | 9.5M | |
| MCA_3.2_1_8_10.CTA of Novartis Study (1).pdf | 2024-09-18 08:06 | 7.5M | |
| MCA_3.2_1_9_11.Biosulin CTA signed.pdf | 2024-09-18 08:06 | 12M | |
| MCA_3.2_1_10_12.promesa.pdf | 2024-09-18 08:05 | 8.2M | |
| MCA_3.2_1_11_13. George CTA_PI Dr Sudhir Kulkarni_MGM.pdf | 2024-09-18 08:05 | 26M | |
| MCA_3.2_1_12_14.THB Signed CTA_merged.pdf | 2024-09-18 08:05 | 6.4M | |
| MCA_3.2_1_13_15.CSIR.pdf | 2024-09-18 08:05 | 5.0M | |
| MCA_3.2_1_14_16.Clinical Trial Agreement_GanjhuVir - 15.pdf | 2024-09-18 08:05 | 164K | |
| MCA_3.2_1_15_17.GSK CTA.pdf | 2024-09-18 08:05 | 3.1M | |
| MCA_3.2_1_16_18.CTA of mgc - 006.pdf | 2024-09-18 08:05 | 7.0M | |
| MCA_3.2_1_17_19.Signed CTA Hexa.pdf | 2024-09-18 08:05 | 4.7M | |
| MCA_3.2_1_18_20.CTA _Dr. Ashish Deshmukh Reliance.pdf | 2024-09-18 08:05 | 16M | |
| MCA_3.2_1_19_21.CSIR.pdf | 2024-09-18 08:05 | 5.0M | |
| MCA_3.2_1_20_22.CTA Rajendra Bohra Zydus.pdf | 2024-09-18 08:05 | 11M | |
| MCA_3.2_1_21_23.CTA Ashish Deshmukh Zydus.pdf | 2024-09-18 08:05 | 11M | |
| MCA_3.2_1_22_24.CTA oF PRA.pdf | 2024-09-18 08:05 | 4.3M | |
| MCA_3.2_1_23_25.CTA AND FUNDING AGREEMENT URTI.pdf | 2024-09-18 08:05 | 6.1M | |
| MCA_3.2_1_24_26.SIGNED CTA.pdf | 2024-09-18 08:05 | 5.5M | |
| MCA_3.2_1_25_.27.BCR-RPD-NEON.pdf | 2024-09-18 08:05 | 243K | |
| MCA_3.2_1_26_28.CTA_DFU_MGM Aurangabad (1).pdf | 2024-09-18 08:06 | 11M | |
| MCA_3.2_1_27_29.02-COV_CTA_Dr.Anand Nikalje_DNDi.pdf | 2024-09-18 08:06 | 97M | |
| MCA_3.2_1_28_30.CTA_ITOLI.pdf | 2024-09-18 08:06 | 16M | |
| MCA_3.2_1_29_31.CTA_Glasshouse_JSS (3) (1).pdf | 2024-09-18 08:06 | 14M | |
| MCA_3.2_1_30_32.Amendment signed CTA_Lipiodol ..pdf | 2024-09-18 08:06 | 263K | |
| MCA_3.2_1_31_33.Scanned CTA IQVIA.pdf | 2024-09-18 08:06 | 2.2M | |
| MCA_3.2_1_32_34.PCV CTA Red Highlighted.pdf | 2024-09-18 08:06 | 17M | |
| MCA_3.2_1_33_35.CTA_Alopecia Areata (2).pdf | 2024-09-18 08:06 | 17M | |
| MCA_3.2_1_34_36.CTA of Lupin.pdf | 2024-09-18 08:06 | 6.6M | |
|
|---|